One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology.
Wieland D MüskensSanne A A Rongen-van DartelSteven TeerenstraEddy M M AdangPiet L C M van RielPublished in: Rheumatology advances in practice (2020)
Non-mandatory transition from etanercept originator to its biosimilar using an opt-in approach in a setting promoting shared decision-making resulted in a higher discontinuation of etanercept compared with the historical cohort. This could be attributed largely to the nocebo effect.